1. Home
  2. SVCO vs TSHA Comparison

SVCO vs TSHA Comparison

Compare SVCO & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SVCO
  • TSHA
  • Stock Information
  • Founded
  • SVCO 1984
  • TSHA 2019
  • Country
  • SVCO United States
  • TSHA United States
  • Employees
  • SVCO N/A
  • TSHA N/A
  • Industry
  • SVCO
  • TSHA Biotechnology: Pharmaceutical Preparations
  • Sector
  • SVCO
  • TSHA Health Care
  • Exchange
  • SVCO NYSE
  • TSHA Nasdaq
  • Market Cap
  • SVCO 221.9M
  • TSHA 262.4M
  • IPO Year
  • SVCO 2024
  • TSHA 2020
  • Fundamental
  • Price
  • SVCO $4.33
  • TSHA $1.45
  • Analyst Decision
  • SVCO Strong Buy
  • TSHA Strong Buy
  • Analyst Count
  • SVCO 6
  • TSHA 8
  • Target Price
  • SVCO $20.50
  • TSHA $6.63
  • AVG Volume (30 Days)
  • SVCO 113.0K
  • TSHA 2.4M
  • Earning Date
  • SVCO 05-14-2025
  • TSHA 05-13-2025
  • Dividend Yield
  • SVCO N/A
  • TSHA N/A
  • EPS Growth
  • SVCO N/A
  • TSHA N/A
  • EPS
  • SVCO N/A
  • TSHA N/A
  • Revenue
  • SVCO $59,680,000.00
  • TSHA $8,333,000.00
  • Revenue This Year
  • SVCO $18.77
  • TSHA N/A
  • Revenue Next Year
  • SVCO $16.01
  • TSHA N/A
  • P/E Ratio
  • SVCO N/A
  • TSHA N/A
  • Revenue Growth
  • SVCO 10.02
  • TSHA N/A
  • 52 Week Low
  • SVCO $3.55
  • TSHA $1.05
  • 52 Week High
  • SVCO $21.59
  • TSHA $4.32
  • Technical
  • Relative Strength Index (RSI)
  • SVCO N/A
  • TSHA 51.66
  • Support Level
  • SVCO N/A
  • TSHA $1.13
  • Resistance Level
  • SVCO N/A
  • TSHA $1.36
  • Average True Range (ATR)
  • SVCO 0.00
  • TSHA 0.14
  • MACD
  • SVCO 0.00
  • TSHA 0.01
  • Stochastic Oscillator
  • SVCO 0.00
  • TSHA 94.12

About SVCO SILVACO GROUP INC

Silvaco Group Inc is a provider of technology computer aided design ("TCAD") software, electronic data automation ("EDA") software and semiconductor intellectual property ("SIP"). TCAD, EDA and SIP solutions enable semiconductor and photonics companies to increase productivity, accelerate their products' time-to-market and reduce their development and manufacturing costs. It is developing the "technology behind the chip" and providing solutions that span from atoms to systems, starting with providing software for the atomic level simulation of semiconductor and photonics material for devices, to providing software and SIP for the design and analysis of circuits and system level solutions.

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

Share on Social Networks: